Claims for Patent: 4,536,386
✉ Email this page to a colleague
Summary for Patent: 4,536,386
| Title: | Method of controlling emesis caused by cisplatin in cancer chemotherapy |
| Abstract: | High dosages of metoclopramide or a pharmaceutical salt thereof is administered intravenously to human cancer patients undergoing cisplatin chemotherapy to prevent emesis. |
| Inventor(s): | Keenan; Robert E. (Richmond, VA) |
| Assignee: | A. H. Robins Company, Inc. (Richmond, VA) |
| Application Number: | 06/508,367 |
| Patent Claims: |
1. A method for alleviating emesis in human cancer patients caused by cisplatin chemotherapy which comprises administering about 5 to 18 mg of metoclopramide or a
pharmaceutically acceptable salt thereof per kg of patient body weight over a period of time spanning about 30 minutes prior to cisplatin administration through the post administration period, said metoclopramide or the pharmaceutically acceptable salt
thereof being administered either continuously or as 4 to 7 individually spaced dosages about 11/2 to 3 hours apart.
2. The method of claim 1 wherein the metoclopramide or a pharmaceutically acceptable salt thereof is administered intraveneously in the presence of a liquid carrier therefor. 3. The method of claim 1 wherein the metoclopramide or a pharmaceutically acceptable salt thereof is divided into 4 to 7 individually spaced dosages which are administered about 11/2 to 3 hours apart. 4. The method of claim 3 wherein the amount of cisplatin administered is about 100 mg/square meter or less of patient body surface and each of the individually spaced dosages are comprised of about 1 mg contained metoclopramide per kg of body weight. 5. The method of claim 3 wherein the amount of cisplatin administered is at or above about 120 mg/square meter of patient body surface and each of the individually spaced dosages are comprised of about 2-3 mg contained metoclopramide per kg of body weight. 6. The method of claim 1 wherein the monohydrochloride monohydrate salt of metoclopramide is used 7. The method of claim 1 wherein the metoclopramide or a pharmaceutically acceptable salt thereof is administered as a continuous infusion. |
